Why Mast Cell Activation Syndrome Awareness Day Matters in Canada

Every October 20, people around the world recognize International Mastocytosis and Mast Cell Diseases Awareness Day. In Toronto, seeing the CN Tower lit in purple has become a powerful symbol for a community that is too often invisible.

I was there for the tower’s inaugural lighting in 2023. I was proud, emotional and hopeful. A landmark cannot diagnose or treat anyone, but visibility matters when so many people are still struggling to find language for what is happening in their bodies, and clinicians with the knowledge and capacity to help.

For me, awareness is not a decorative gesture. It is a starting point for better education, research and care.

What is mast cell activation syndrome?

Mast cells are immune cells involved in allergic responses and other protective functions. In mast cell activation syndrome, or MCAS, a person experiences repeated episodes consistent with mast-cell mediator release. Depending on the person and episode, symptoms may involve more than one body system and can include flushing, hives, swelling, breathing difficulty, gastrointestinal distress, rapid heart rate, low blood pressure or fainting and anaphylaxis.

MCAS is complex, and symptoms alone are not enough to establish the diagnosis. Consensus-based evaluation considers the pattern of episodes, objective evidence of mediator release and response to appropriate treatment while other explanations are assessed. That complexity is one reason people need clinicians who understand the criteria rather than relying on either dismissal or oversimplification.

This article is not a diagnostic guide. It is an account of what the gaps in awareness and care can mean for a patient.

When access to care disappears

Receiving a diagnosis did not end my search for care. Specialist capacity in Canada is limited, and changes in that small network can leave patients without continuity, guidance or a clear place to turn.

That uncertainty affects more than a medical chart. It shapes whether someone feels safe trying a medication, having a procedure, travelling, eating outside their home or going to an emergency department where staff may not be familiar with their condition.

People should not have to become experts in system navigation simply to maintain access to medically necessary care. They should not have to travel out of country or pay privately because domestic expertise is unavailable. And they should not have to prove, at every new appointment, that a complex inflammatory condition is real.

Visibility must lead somewhere

Landmark lightings create a moment in which people ask, “Why purple?” The answer should lead beyond a hashtag.

Meaningful progress includes:

• evidence-informed education for health professionals;
• clear referral and diagnostic pathways;
• sustainable specialist capacity and continuity of care;
• Canadian research that includes patient partners from the beginning; and
• respectful care for patients whose symptoms are complex, episodic or difficult to capture during a short appointment.

Awareness also means being careful with information. MCAS has attracted attention online, but visibility can spread both recognition and misinformation. Patients deserve accurate explanations, honest discussion of uncertainty and care grounded in current evidence.

What allies can do

You do not need to understand every mediator or diagnostic test to support someone living with MCAS.

You can believe people when they describe their limits. You can respect fragrance-free requests and other individualized accommodations. You can avoid assuming that a person who looks well is symptom-free. You can share credible resources, support patient-led organizations and ask decision-makers how Canada is building capacity for underrecognized complex inflammatory conditions.

Most importantly, you can listen without turning someone’s need for care into a debate about whether they are sick enough to deserve it.

More than one day

October 20 gives the community a focal point, but our needs do not disappear when the purple lights turn off.

The goal is not awareness for its own sake. It is a health-care system in which a patient can receive an informed assessment, maintain appropriate care and participate in decisions without being treated as a problem for being complex.

When the system leaves people isolated, community visibility reminds us that we are not alone. When that visibility is connected to education, research and accountability, it can become something more: a path toward change.

Further reading

• Mast Cell Activation Syndrome — Mast Cell Action
• Emily Foucault on Canada’s MCAS care crisis — Healthy Debate

This article shares lived experience and general information. It is not medical advice or a diagnostic resource.